Deep Brain Stimulation (DBS) is an emerging treatment strategy for patients with intractable depression with imaging playing a crucial role in the development, testing and refinement of the procedure. Multimodal modeling of structural and functional connections combined with real-time behavioral and electrophysiological metrics is now used to more precisely identify the optimal target location as well as track long-term stimulation effect. Together these studies offer a unique perspective on critical pathways and mechanisms mediating antid effects of DBS, and on the pathophysiology of treatment resistant depression more generally.
Abstract
The limitations of standard antidepressant treatments are well known, they work for too few patients and their beneficial effects emerge too slowly. APPROACH: The purpose of this presentation is to briefly describe the context leading to the discovery of the antidepressant effects of ketamine in humans, to characterize our current understanding of the profile of ketamine's efficacy and ways that it is entering routine clinical treatment, to consider the management of risks associated with ketamine treatment, and to consider emerging alternatives to ketamine. Emerging studies also point to ketamine effectiveness in PTSD. CONCLUSIONS: The rapidity (onset within 24 hours) and magnitude (50%-75% clinical response rate, even in treatment-resistant depression populations) of the efficacy of ketamine suggest that it could be a new and important role in the treatment of mood disorders where clinical response is needed urgently or where there has been inadequate response to other treatments. Disclosure: Dr. Krystal is a co-proponent of a use patent related to the intranasal administration of ketamine for the treatment of depression that has been licensed by Johnson and Johnson. Title: Establishment and escalation of cocaine use is determined by distinct patterns of striatal dopamine signaling Abstract The basal ganglia provide brain structure for the selection of motivated actions. Dopamine neurotransmission in the striatum, the main input nucleus of the basal ganglia, is central to regulating motivated actions. Limbic parts of the striatum are thought to be involved in the acquisition of motivated behavior and sensorimotor parts in the automation of these actions. Recent findings show that contrary to the assumption of a uniform dopamine signal throughout the brain, dopamine release is region-specific. In this talk, I will present studies that utilized electrochemical detection of real-time dopamine release in rats self-administering cocaine in order to further explore the role of region-specific striatal dopamine signaling in substance use. My results demonstrate that phasic dopamine release in the sensorimotor striatum emerges progressively during drug taking over the course of weeks. This emergent dopamine signaling is dependent on antecedent activity in the limbic striatum. Thus, the current findings identify a striatal hierarchy that is instantiated during the expression of established responses to obtain cocaine. Furthermore, I show that a sub-population of rats increased their drug intake progressively. A development that can be attributed to a loss of dopamine signaling in the limbic striatum, but not to changes in the sensorimotor striatum. Thus, this suggests that drug consumption escalates in order to compensate for diminished limbic signaling and to maintain a preferred level of dopamine neurotransmission. These findings will be discussed in light of the putative role of different striatal domains in behavioral flexibility and their potential therapeutic relevance.
Speaker 2: Yolanda Peña-Oliver, UK
Title: Preventing the expression of a drug seeking habit triggers aberrant cocaine seeking behaviour at relapse Yolanda Peña-Oliver, Mickaёl Puaud, Chiara Giuliano, David Belin and Barry J Everitt Abstract Cocaine addiction is increasingly considered to stem from the development of maladaptive, stimulus bound, drug seeking habits that both contribute to the maintenance of drug use despite aversive consequences, and also to high rates of relapse. However because relapse by definition occurs only after a period of abstinence, the relative contribution of habits and pharmacological withdrawal from the drug to relapse is unknown. In this study we demonstrate that preventing rats from expressing their drug seeking habits after forced abstinence results in aberrant, compulsive drug seeking behaviour at relapse. Thus, ListerHooded rats were trained under a fixed-interval (FI) 15-min schedule or a FI 15 (FR10:S) second order schedule of reinforcement, the latter having been shown to recruit stimulus bound, dorsolateral striatum-dependent, maladaptive habits. Indeed, in this procedure every ten active lever presses produces the presentation of a 1s (CS) so that rats respond more vigorously for the drug in the presence, than in the absence, of the drug CS. The results showed that a 3-day forced abstinence period increased cocaine seeking responses only in the group trained under second-order schedule of reinforcement, while cocaine abstinence had no effect in the FI 15 group who responded for cocaine but without earned drug cue presentations. In order to test if this increase in responding depended on the motivational effect of pharmacological withdrawal from cocaine, rats then received non contingent cocaine injections while being prevented from responding for the drug for a 3-day "instrumental seeking abstinence" period. The results showed that despite receiving the same amount of cocaine as during the self-administration sessions, only the rats with a history of CS-dependent cocaine seeking habits displayed the robust increase in cocaine seeking after abstinence. These results strongly suggests that the expression of maladaptive seeking habits, rather than pharmacological drug withdrawal itself, contribute to addiction by invigorating drug seeking behaviour in individuals under abstinence, indicating a core psychological component of the addiction cycle. (1) posit that habitual or automated substance consumption plays a prominent role in later stages of addiction. While this hypothesis was mainly examined for stimulant and opioid addictions, its implication for the understanding of alcohol use disorders and their treatments is largely unexplored. Methods: To examine the association between consumption patterns and neural cue-reactivity, we tested social drinkers and alcohol-dependent patients using a cue-reactivity task using functional Magnetic Resonance Imaging (fMRI). Additionally we assessed automated alcohol consumption (2) and obsessivecompulsive craving (3) . Furthermore, we examined the association between neural cue-reactivity and treatment outcome in recently detoxified alcohol-dependent patients. Results: In social drinkers, increased obsessive-compulsive craving was associated with higher activation in the dorsal and lower activation in the ventral striatum (4). Alcohol-dependent patients, who reported uncontrolled alcohol consumption and consumption without awareness, showed reduced neural cue-reactivity in the insula, the occipital cortex, fusiform gyrus, medial frontal cortex as well as in limbic areas. In contrast, automated craving related to unawareness and loss of control, were positively associated with brain activation in the thalamus, the red nucleus and the putamen. Besides this, high neural cue-reactivity in the ventral striatum and orbitofrontal cortex of alcohol-dependent patients was associated with early relapse (5) . Discussion: Our results emphasize the importance of habitual and automated substance consumption in later stages of addiction. In these stages the initial hedonic effects decrease. This may be indicated by lower neural cue-reactivity in the insula and reward-related brain areas. Patients with automated or obsessivecompulsive alcohol consumption might no longer be attracted to appetitive external alcohol-associated stimuli. Instead, processing of alcohol-cues might be similar to habit-processing in these patients. The association between high neural cue-reactivity and poor treatment outcome indicates that patients with high cue-reactivity might benefit from treatment aiming to reduce responses to alcohol-associated cues. In contrast, patients with low neural cue-reactivity and automated consumption patterns might be candidates for cognitive behavioral treatment, where patients learn how to experience craving consciously and avoid the automated initiation of alcohol consumption.
